Showing results (131-140 of 224) with videos related to
Sort By:
Pageof 23
Clinical Neuropathology|December 24, 2013
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)Anna Sophie Berghoff, Gerda Ricken, Georg Widhalm, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 9, 2004
Glioblastoma with spinal seedingNegar Fakhrai, Thomas Czech, Karin Diekmann, et al.The American Journal of Surgical Pathology|June 30, 2004
Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymomaStefan Wolfsberger, Ingeborg Fischer, Romana Höftberger, et al.Scientific Reports|July 10, 2024
Screening for oncogenic AF1q expression predicts disease recurrence in gastric cancer patientsElisabeth S Gruber, Georg Oberhuber, Michaela Schlederer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancerBarbara Bachtiary, Monika Schindl, Richard Pötter, et al.Clinical Chemistry|July 21, 2011
Simplified newborn screening protocol for lysosomal storage disordersThomas F Metz, Thomas P Mechtler, Joseph J Orsini, et al.Journal of Neuro-Oncology|July 21, 2016
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, et al.Annals of Surgical Oncology|April 27, 2011
Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expressionPeter Birner, Bettina Jesch, Julia Friedrich, et al.Oncology Reports|June 18, 2002
Prognostic relevance of p53 protein expression in glioblastomaPeter Birner, Maria Piribauer, Ingeborg Fischer, et al.Haematologica|October 14, 2011
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinHarald Herrmann, Sabine Cerny-Reiterer, Karoline V Gleixner, et al.Pageof 23